

ASX ANNOUNCEMENT

CLEANSING NOTICE UNDER SECTION 708A(5)(e) OF THE CORPORATIONS ACT

SYDNEY, Friday, 7 January 2022: Anagenics Limited (ASX:AN1) today issued 803,858 fully paid ordinary shares (**Shares**) as set out in the Appendix 2A dated today. The Shares were issued to Director, Dennis Eck in lieu of his director fees as approved by the Company's Shareholders at the Annual General Meeting held on 9 December 2021.

This notice is being given under section 708A(5)(e) of the Corporations Act 2001 (Cth) (**Corporations Act**) and the Company advises that:

1. The shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act;
2. As at the date of this notice, the Company has complied with:
 - a. the provisions of Chapter 2M of the Corporations Act as they may apply to the Company; and
 - b. section 674 of the Corporations Act; and
3. As at the date of this notice there is no information that is "excluded information" within the meaning of sections 708A(7) and 708A(8) of the Corporations Act.

Authorised for release by the Board of Anagenics Limited.

Contact

Maria Halasz, CEO
T +612 9221 6830

Anagenics Limited (ASX: AN1)

Anagenics is a health and beauty-tech business growing shareholder value through the global distribution and sales of its proprietary brands of differentiated, clinically validated anti-aging solutions. Advangen is Anagenics wholly owned subsidiary engaged in the development and sale of first in class, best in class, clinically validated products for hair, skin and body. For further information, please see www.anagenics.com and www.evolisproducts.com.au.

